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Abstract
Background: Recent investigations on the antifungal properties of essential oil of Melaleuca
alternifolia Cheel (Tea Tree Oil, TTO) have been performed with reference to the treatment of
vaginal candidiasis. However, there is a lack of in vivo data supporting in vitro results, especially
regarding the antifungal properties of TTO constituents. Thus, the aim of our study was to
investigate the in vitro and the in vivo anti-Candida activity of two critical bioactive constituents of
TTO, terpinen-4-ol and 1,8-cineole.
Methods:  Oophorectomized, pseudoestrus rats under estrogen treatment were used for
experimental vaginal infection with azole (fluconazole, itraconazole) -susceptible or -resistant
strains of C. albicans. All these strains were preliminarily tested for in vitro susceptibility to TTO,
terpinen-4-ol and 1,8-cineole for their antifungal properties, using a modification of the CLSI
(formerly NCCLS) reference M27-A2 broth micro-dilution method.
Results: In vitro minimal inhibitory concentrations (MIC90) values were 0.06% (volume/volume) for
terpinen-4-ol and 4% (volume/volume) for 1,8-cineole, regardless of susceptibility or resistance of
the strains to fluconazole and itraconazole. Fungicidal concentrations of terpinen-4-ol were
equivalent to the candidastatic activity. In the rat vaginal infection model, terpinen-4-ol was as active
as TTO in accelerating clearance from the vagina of all Candida strains examined.
Conclusion: Our data suggest that terpinen-4-ol is a likely mediator of the in vitro and in vivo
activity of TTO. This is the first in vivo demonstration that terpinen-4-ol could control C. albicans
vaginal infections. The purified compound holds promise for the treatment of vaginal candidiasis,
and particularly the azole-resistant forms.
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Background
Recently, essential oils and their components distilled
from vegetable materials have been found to express anti-
microbial, antioxidant, pharmacological and anticancer
activities [1-3]. Among the essentials oils, Australian tea
tree oil (TTO) is the most important, because it demon-
strated a broad spectrum of biological activities. The Euro-
pean Pharmacopoeia [4] and the International Standard
ISO 4730 [5] require TTO to be obtained by steam distil-
lation from the foliage and terminal branchlets of Mela-
leuca alternifolia Cheel, and to have a minimum content of
30% of terpinen-4-ol and a maximum content of 15% of
1,8-cineole. Terpinen-4-ol is the major TTO component
and has shown strong antimicrobial and anti-inflamma-
tory properties [6,7], while 1,8-cineole is probably an
undesirable allergen in TTO products [8]. Despite recent
investigations on the biological properties of TTO, there
still remains a paucity of in vivo data confirming and
strengthening the in vitro results. This particularly applies
to antifungal properties of TTO constituents. In a previous
paper, we demonstrated the capacity of TTO to accelerate
the clearance of Candida albicans, a prime agent of acute
and recurrent forms of vulvovaginitis [9] from experimen-
tally infected-rat vagina. Building on this promising result
we have addressed the in vitro and the in vivo anti-Candida
activity of two critical constituents of TTO, namely ter-
pinen-4-ol (TERP) and 1,8-cineole (CIN). This has been
done with standardised methods and the use of a recog-
nised model of estrogen-induced vaginal candidiasis in
rats [10].
Methods
Melaleuca alternifolia Cheel (tea tree) oil and 
components
Australian Melaleuca alternifolia (Maiden and Betch) Cheel
oil, supplied by Variati (Milan, Italy), was analysed for the
exact determination of single constituents and the correct
conditions for storage, as shown in the Results (see Table
1). Terpinen-4-ol purchased from Fluka (Buchs, Switzer-
land) and 1,8-cineole from Sigma-Aldrich (St Louis, MO,
USA), were used as positive markers. All components used
were > 97% pure.
Gas chromatography (GC-FID) and gas-chromatography-
mass spectrometry (GC-MS)
Gas chromatography appliances used included a Perkin
Elmer Auto System equipped with two fused-silica SPB
columns (60 m × 0.25 mm i.d.; film thickness 0.25 μm),
mounted in parallel in the same oven, with two detectors:
FID and Q-Mass 910 (electron ionization 70 eV electron
energy, transfer line 220°C). Carrier gas was oxygen and
moisture-free helium obtained from a SUPELCO High
Capacity Heated Carrier Gas Purifier (Sigma-Aldrich,
Milan), provided with an OMI-2 indicating tube, at an
average flow rate of 1 mL/min. The oven temperature pro-
gramme was 60°C for 4 min, then 2°C/min until 180°C
was reached, then increased 3°C/min until 250°C. The
detector and the injector temperature was 280°C. The vol-
ume of injected essential oil or pure substance was 0.1 μL,
and the split ratio was 1:50. Two distinct data systems
were connected to the GC-FID or GC-MS: Turbochrom
and Q-mass Analytical Workstation Software (Perkin-
Elmer, Milan) with a NIST/EPA/MSDC Mass Spectral
database.
Antifungal agents
A stock solution of fluconazole (FLC) technical grade
(5000 mg/L; Pfizer Inc., NY, USA) was prepared in sterile
distilled water, and a stock solution of itraconazole (ITC)
technical grade (1000 mg/L; Janssen Pharmaceutica,
Beerse, Belgium) was prepared in polyethylene glycol 400,
by heating at 75°C for 45 min.
Yeast isolates
A total of 49 clinical isolates of C. albicans were used
throughout this study. All were isolated from oropharyn-
geal swabs of HIV-seropositive subjects. Seven isolates
were resistant to FLC, 13 to ITC and 6 to both drugs, as
established by international breakpoint standards [11].
All clinical isolates were identified according to morphol-
ogy on corn meal agar, followed by germ tube formation
and assimilation-fermentation profiles in the API 20 sys-
tem (bioMérieux, Marcy l'Étoile, France), as reported else-
Table 1: Chemical composition of the Melaleuca alternifolia Cheel 
essential oil
Components Kovats Index, K.I.a Percentage, %
α-Thujene 931 0.94
α-Pinene 939 2.42
Sabinene 976 0.40
β-Pinene 980 0.73
Myrcene 991 0.87
α-Phellandrene 1005 0.34
α-Terpinene 1018 9.76
p-Cymene 1026 2.82
Limonene 1031 1.75
1,8-Cineole 1033 3.57
γ-Terpinene 1062 20.65
Terpinolene 1088 3.71
Terpinen-4-ol 1168 42.35
α-Terpineol 1189 3.09
Aromadendrene 1439 0.94
δ-Cadinene 1524 1.05
aThe substances were reported in increasing order of Retention Time 
expressed as Kovat's IndexBMC Infectious Diseases 2006, 6:158 http://www.biomedcentral.com/1471-2334/6/158
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where [12]. Reference strains were also used for
comparative purposes, as listed in Table 2. Candida parap-
silosis ATCC 22019 and Candida krusei ATCC 6258 were
also quality control (QC) isolates.
Determination of minimum inhibitory and fungicidal 
concentration
Susceptibility testing of C. albicans and other yeasts to
TTO, terpinen-4-ol, 1,8-cineole, FLC and ITC was per-
formed according to the Clinical and Laboratory Stand-
ards Institute (CLSI, formerly NCCLS) method for broth
dilution antifungal susceptibility testing of yeasts [11].
Each antifungal compound was diluted using RPMI 1640
medium with L-glutamine, without sodium bicarbonate
(Sigma Chemical Co., St Louis, MO, USA) and buffered to
pH 7.0 with 0.165 M 4-Morpholinepropanesulfonic acid
(MOPS) buffer (Sigma). Aliquots of 50 μL of two-fold
dilutions of drug solutions were dispensed in 96-well
microtitre plates. The final concentration of the antifungal
agents ranged from 0.0078 to 4 mg/L for ITC, 0.125 to 64
mg/L for FLC and 0.0078% to 4% v/v for TTO, terpinen-
4-ol and 1,8-cineole. Tween-80 (final concentration
0.001% v/v) was included to facilitate oil solubility [13].
At this concentration, no inhibitory effect on yeast growth
was shown by the detergent. The cell density of the sus-
pensions was estimated by direct cell count using a Thoma
camera, and adjusted to a cell density ranging from 0.5 ×
103 to 2.5 × 103 cfu/mL (twice the final inoculum size); 50
μL was added to each well of the micro-dilution plate, fol-
lowed by incubation for 48 hr at 35 C°. Minimum inhib-
itory (MIC) and fungicidal concentrations (MFC) were
determined. The MIC was defined as the lowest concentra-
tion that produced a 50% reduction of growth, compared
with growth of the drug-free control growth, and the MFC
as the lowest drug concentration resulting in the death of
99.9% or more of the initial inoculum. To determine
MFCs, 10 μL of broth was taken from the well without
microbial growth, inoculated onto Sabouraud's dextrose
agar (SDA) and incubated at 35°C. After 48 hr the cfu
were counted to assess viability. Each experiment was per-
formed in triplicate, independently. The minimum con-
centration of drug that inhibited 90% and 50% of the
isolates tested was defined as MIC90 and MIC50. The crite-
ria for definition of susceptibility/resistance to FLC/ITC
were those established by the CLSI [11].
Experimental vaginal infection
A rat vaginal model was used for the experimental vaginal
infection, as previously described [14]. Experiments were
carried out with FLC-susceptible and -resistant strains of
C. albicans. Two independent experiments with each fun-
gal strain were conducted and in each experiment groups
of five rats were used. Oophorectomized female Wistar
rats (80–100 g; Charles River Calco, Italy) were injected
subcutaneously with oestradiol benzoate 0.5 mg (Estradi-
olo, Amsa Farmaceutici srl, Rome, Italy). Six days after the
first oestradiol dose, all animals were inoculated intravag-
inally with 107 yeast cells of each C. albicans strain tested
in 0.1 mL of saline. The strains used for the challenge were
C. albicans SA-40, which was susceptible to both FLC and
ITC, and AIDS-68, which was resistant to both these
drugs. The inoculum was dispensed into the vaginal cavity
through a syringe equipped with a multipurpose cali-
brated tip (Combitip; PBI, Milan, Italy). The yeast cells
had been grown previously in YPD broth (yeast extract
1%, peptone 2%, dextrose 2%) at 28°C on a gyrator
shaker (200 rpm), harvested by centrifugation (1500 g),
washed, counted in a haemocytometer, and suspended to
the required number in saline solution. The number of
Table 2: In vitro antifungal activity of tea-tree oil, terpinen-4-ol, 1,8-cineole and comparatorsa in reference strains
Organism FLC ITC TTO TERP CIN
MIC mg/L MIC mg/L MIC %v/v MIC %v/v MFC %v/v MIC %v/v MFC %v/v
C. albicans ATCC 24433 0.25 0.06 0.25 0.06 0.125 > 4.0 > 4.0
C. albicans ATCC 76615 0.125 0.06 0.25 0.03 0.125 > 4.0 > 4.0
C. albicans ATCC 90029 0.125 0.03 0.25 0.03 0.125 4.0 4.0
C. albicans ATCC 10231 0.125 0.03 0.25 0.06 0.06 > 4.0 > 4.0
C. tropicalis ATCC750 1.0 0.125 0.06 0.03 0.125 > 4.0 > 4.0
C.parapsilosis ATCC 22019 2.0 0.06 0.125 0.03 0.125 > 4.0 > 4.0
C. krusei ATCC 6258 32.0 0.25 0.25 0.03 0.125 > 4.0 > 4.0
C. glabrata ATCC 90030 4.0 0.125 0.06 0.03 0.125 2.0 > 4.0
S. cerevisiae ATCC 9763 4.0 0.25 n.a. 0.03 0.125 4.0 > 4.0
C.neoformans ATCC 90112 2.0 0.03 0.03 0.015 0.06 2.0 > 4.0
C. neoformans ATCC 90113 4.0 0.125 n.a. 0.015 0.06 1.0 n.a.
aFLC = Fluconazole; ITC = Itraconazole; n.a. = not assessedBMC Infectious Diseases 2006, 6:158 http://www.biomedcentral.com/1471-2334/6/158
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cells in the vaginal fluid was counted by culturing 1 μL
samples (using a calibrated plastic loop, Disponoic; PBI)
taken from each animal, on SDA containing chloram-
phenicol (50 mg/L) as previously described. The kinetics
of  Candida  vaginal infection were monitored by the
number of cfu/mL of vaginal lavage fluid. TTO and ter-
pinen-4-ol were administered intravaginally (0.1 mL at
1%, 2.5% and 5%, in 0.001% Tween-80 for TTO; 0.1 mL
at 1%, in 0.001% Tween-80 for terpinen-4-ol), at 1, 24
and 48 hr after intravaginal C. albicans challenge. Rats
receiving FLC (3 doses of 100 μg intravaginally) or Tween-
80 served as positive or negative controls, respectively.
The infection was monitored for at least 21 days after the
challenge, with vaginal fluid sampling usually being made
at 1, 24 and 48 hr, then on days 5, 7, 14 and 21. The ani-
mal experimentation referred to in this paper was
approved by the ad hoc committee of the Istituto Superi-
ore di Sanità, Rome, Italy.
Statistical analysis
The significance of mean cfu differences in the vaginal
infection was assessed by Student's t-test and set at P <
0.05 (two tailed).
Results
Chemical identification and quantitative estimations
TTO composition was determined by comparing GC
retention times, the Kovat's Indices (15) and GC/MS spec-
tra with those of the co-injected reference substances. In
the absence of reference substances, the structure of the
components was tentatively assigned by the Officinal
NIST/EPA/MSDL Spectral Library. Quantitative data were
based on peak area normalisation without using a correc-
tion factor. The substances and their relative composition
are shown in Table 1. The oil was a terpinen-4-ol type
according to the European Pharmacopoeia [4] and the
International Standard ISO 4730:1996 [5].
Antifungal activity
Terpinen-4-ol and 1,8-cineole were compared with the
mother oil for their antifungal activity in vitro. This activity
included FLC and ITC resistant isolates, as shown in
Tables 2 and 3. Terpinen-4-ol and 1,8-cineole inhibited
all isolates tested, though with different MIC values (Table
3). In fact the MICs ranged from 0.015% to 0.06% for ter-
pinen-4-ol and from 1% to > 4% v/v for 1,8-cineole.
MIC90 values were 0.06% for terpinen-4-ol and 4 % v/v for
1,8-cineole, regardless the azole-susceptibility or resist-
ance of the strains. Overall, the antifungal activity
(MICs90)  in vitro was twice higher for terpinen-4-ol
(0.06% v/v) and four times lower for 1,8-cineole (4% v/
v), in comparison to TTO activity (0.25% v/v) in suscepti-
ble strains of C. albicans, while it was (MIC90) three times
higher for terpinen-4-ol (0.06% v/v) and three times
lower for 1,8-cineole (4% v/v), in comparison to TTO
activity (0.5% v/v) in resistant strains of C. albicans. Ter-
pinen-4-ol was also fungicidal as determined by MFC.
Generally, MFCs90 and MICs90 of terpinen-4-ol (0.06% v/
v) coincided in azole susceptible strains. In contrast,
MFCs90 (0.5% v/v) were three times higher for azole resist-
ant strains of C. albicans (Table 4). The component 1,8-
cineole was also fungicidal as determined by MFC. Table
3 also shows the data for the mother compound mixture
TTO, which confirms previously published data by our
group [10]. The MIC values for TTO ranged from 0.06% to
0.5% v/v. MICs90 were 0.25% v/v for azole-susceptible
and 0.5% v/v for azole-resistant C. albicans strains. At the
MIC value and confirming previous results [10], TTO was
generally also fungicidal, as determined by MFC. The MIC
and MFC coincided for each isolate. TTO was also active
against FLC-, ITC-resistant strains or both, with MICs50 of
0.25% v/v and MICs90 of 0.5% v/v, for both drugs. In
Table 3, MICs for FLC, ITC, TTO, terpinen-4-ol, 1,8-cine-
ole are shown for comparative purposes.
Experimental vaginal infection
After establishing activity in vitro, we examined and com-
pared the activity of terpinen-4-ol with the mother mix-
ture TTO in vivo. Cineole was excluded from this
investigation because of its weak in vitro antifungal activ-
Table 3: In vitro anti-C.albicans activity of tea tree oil, terpinen-4-
ol, 1,8-cineole and comparatorsa
MICb Drug Organism
Candida albicansc (35)e Candida albicansd (14)e
MIC50 FLC 0.125 64.0 (7)d
ITC 0.03 4.0 (13)
TTO 0.125 0.25
TERP 0.03 0.06
CIN 2.0 4.0
MIC90 FLC 0.25 64.0
ITC 0.03 4.0
TTO 0.25 0.5
TERP 0.06 0.06
CIN 4.0 4.0
MIC range FLC 0.125–2.0 32.0–64.0
ITC 0.0078-0.5 4.0
TTO 0.06-0.5 0.25-0.5
TERP 0.015-0.06 0.03-0.06
CIN 1.0>4.0 > 4.0
aFluconazole (FLC); Itraconazole (ITC); bMICs are expressed in mg/L 
(FLC and ITC) or in % v/v (TTO, TERP, CIN); cFLC- and ITC- 
susceptible isolates. The MICs for the QC of C. krusei were 32 mg/L 
for FLC and 0.25 mg/L for ITC, 0.25% v/v for TTO, 0.06% v/v for 
TERP and  4% v/v for CIN. The MICs for the QC of C. parapsilosis 
were 2.0 mg/L for FLC and 0.06 mg/L for ITC, 0.125% v/v for TTO, 
0.03 % v/v for TERP and 4% v/v for CIN; dFLC, ITC or both, resistant 
isolates; six isolates were cross resistant; eIn parenthesis, the number 
of strains tested.BMC Infectious Diseases 2006, 6:158 http://www.biomedcentral.com/1471-2334/6/158
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Table 4: In vitro fungicidal activity of tea-tree oil, terpinen-4-ol, 1,8-cineole and comparatorsa
MFC50 MFC90
Organism No. of 
isolates
FLC 
(mg/L)
ITC 
(mg/L)
TTO 
(%v/v)
TERP 
(%v/v)
CIN 
(%v/v)
FLC 
(mg/L)
ITC 
(mg/L)
TTO 
(%v/v)
TERP 
(%v/v)
CIN 
(%v/v)
Candida 
albicansb
35 > 64 > 4 0.25 0.03 2 > 64 > 4 0.25 0.06 2
Candida 
albicansc
14 > 64(7)c > 4(13) 0.5 0.25 4 > 64 > 4 0.5 0.5 4
aFluconazole (FLC); Itraconazole (ITC);b FLC- and ITC- susceptible isolates. The MICs for the QC of C. krusei were 32 mg/L for FLC and 0.25 mg/L 
for and ITC, 0.25% v/v for TTO, 0.06% v/v for TERP and  4% v/v for CIN. The MFC was 0.125% for TERP. The MICs for the QC of C. parapsilosis 
were 2 mg/L for FLC and 0.06 mg/L for ITC, 0.125% v/v for TTO, 0.03 % v/v for TERP and 4% v/v for CIN. The MFC was 0.125 % v/v for TERP; 
cFLC, ITC resistant isolates or both; six isolates were cross resistant.
Vaginal infection outcome by a fluconazole-susceptible strain C. albicans (SA-40) in oophorectomized, oestradiol-treated rats  inoculated intravaginally with TTO 5% v/v (open squares), 2.5% v/v (open triangles), 1% v/v (open circles), terpinen-4-ol 1% v/v  (filled triangles), fluconazole 100 μg (filled circles), Tween-80 0.001% v/v (control; filled squares) at 1, 24 and 48 hr after intrav- aginal C. albicans challenge (107 cells in 0.1 mL) Figure 1
Vaginal infection outcome by a fluconazole-susceptible strain C. albicans (SA-40) in oophorectomized, oestradiol-treated rats 
inoculated intravaginally with TTO 5% v/v (open squares), 2.5% v/v (open triangles), 1% v/v (open circles), terpinen-4-ol 1% v/v 
(filled triangles), fluconazole 100 μg (filled circles), Tween-80 0.001% v/v (control; filled squares) at 1, 24 and 48 hr after intrav-
aginal C. albicans challenge (107 cells in 0.1 mL). Each curve represents the mean (± S.E.) of cfu of five rats. Data are from one of 
two independent experiments with similar results. At each time point considered, starting from day 2 to day 14, there was a 
statistically significant difference between the cfu of rats treated with fluconazole or TTO 5% or TTO 2.5% or terpinen-4-ol 
and those of the untreated animals.
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ity. We selected an experimental mucosal infection (oes-
trogen-dependent rat vaginitis) in which the animals were
challenged with either a FLC-ITC-susceptible (SA-40) or a
FLC-resistant (AIDS-68) C. albicans strain. Two experi-
ments were performed with each strain, and these pro-
duced substantially overlapping results. Figures 1 and 2
show the details of one of the two experiments. As shown
in Figure 1, which refers to results obtained with FLC-sus-
ceptible (SA-40) C. albicans strain, terpinen-4-ol (1% v/v)
exerted a marked acceleration of clearance of the yeast, as
demonstrated by a statistically significant decrease in cfu
counts in the first 2 weeks after the vaginal challenge,
compared with the control (terpinen-4-ol-untreated ani-
mals, only given the Tween-80 diluent). As with all dose
regimens, the infection was cleared in 3 weeks, whereas
the untreated control rats remained infected (approxi-
mately 2.5 × 104 C. albicans cfu/mL of vaginal fluid). FLC
treatment, used as a positive control, showed a pattern of
clearance comparable to that induced by terpinen-4-ol.
No effect on the rate of fungal clearance was observed in
rats treated with terpinen-4-ol diluent Tween-80. In com-
parative terms, the acceleration of Candida clearance in
rats treated with 1% terpinen-4-ol solution did substan-
tially overlap the activity of a 5% v/v solution of TTO and
statistically significant compared to 1% v/v TTO. As
shown in Figure 2, terpinen-4-ol (1% v/v) also caused a
rapid clearance of the FLC-resistant strain from the vagina
of experimentally infected rats. In this case however, TTO
Vaginal infection outcome by fluconazole-itraconazole resistant strain C. albicans (AIDS-68) in oophorectomized, oestradiol- treated rats inoculated intravaginally with TTO 5% v/v (open squares), 1% v/v (open circles), terpinen-4-ol 1% v/v (filled trian- gles), fluconazole 100 μg (filled circles), Tween-80 0.001% v/v (control; filled squares) at 1, 24 and 48 hr after C. albicans chal- lenge (107 cells in 0.1 mL) Figure 2
Vaginal infection outcome by fluconazole-itraconazole resistant strain C. albicans (AIDS-68) in oophorectomized, oestradiol-
treated rats inoculated intravaginally with TTO 5% v/v (open squares), 1% v/v (open circles), terpinen-4-ol 1% v/v (filled trian-
gles), fluconazole 100 μg (filled circles), Tween-80 0.001% v/v (control; filled squares) at 1, 24 and 48 hr after C. albicans chal-
lenge (107 cells in 0.1 mL). Each curve represents the mean (± S.E.) of the fungal cfu of five rats. At each time point (day1-
day14) there was a statistically significant difference (P < 0.05, Student's t test, two tailed) between the untreated control and 
cfu of rats treated with TTO 5%, TTO 1% and terpinen-4-ol. At scattered day intervals, there was also a statistically significant 
difference (P < 0.05, Student's t test, two tailed) between cfu of rats treated with TTO 5% or terpinen-4-ol and TTO 1% (for 
example day 1).
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(5% v/v) was significantly more active than terpinen-4-ol.
Also of note, the in vitro resistance to FLC did not cause the
strain to be totally unaffected by FLC in vivo.
Discussion
As stated elsewhere [10] the interest in non-conventional,
non-prescription natural medicinals in the field of infec-
tion parallels an increased awareness of side effects of con-
ventional drugs. There is also a necessity in finding new
approaches in the therapy of infections in an era of emerg-
ing and remerging infections and the spread of antimicro-
bial drug resistance. In this line of research, we have
previously shown that one of the most popular natural
medicaments, namely TTO, had a significant curative
effect on experimental vaginal candidiasis in rats [10] in
keeping with a remarkable antifungal activity in vitro, also
previously shown also by other authors [16]. However, no
dissection of the individual constituents was made in pre-
vious studies, and we could not attribute the anticandidal
in vivo activity to any of the numerous TTO constituents.
Based on preliminary observations indicating that 1,8-
cineole and terpinen-4-ol could be involved and are
mostly responsible for this activity, we have in this study
separated these different constituents and investigated
their effects. We specifically examined whether terpinen-
4-ol could mimic the activity of the whole TTO in exerting
a therapeutic effect against both azole-susceptible and
azole-resistant strains of C. albicans in vivo. Here we show
that terpinen-4-ol rather than 1,8-cineole is the most
likely mediator of TTO activity or, at least, a main contrib-
utor of it. Our in vitro data confirm that terpinen-4-ol has
the highest antimicrobial activity and, in contrast, 1,8-cin-
eole exhibited a much lower activity [13,17]. The ter-
pinen-4-ol MIC90  and MFC90  for  C. albicans strains
determined in our study did not match those reported by
other authors against the same fungus [17-20]. MIC90 and
MFC90 for terpinen-4-ol were lower than those of TTO.
Importantly, the MICs90 were always lower even for resist-
ant C. albicans strains. It is of interest that the batch of ter-
pinen-4-ol used had a fungicidal concentration (0.5% v/
v) not equal to the MIC (0.06% v/v) for resistant C. albi-
cans strains, thus demonstrating the rapid cytocidal activ-
ity of this main component. This was also demonstrated
by the time-kill experiments, as shown by others [21]. The
interpretation of susceptibility was easy because a distinct
endpoint of growth inhibition was produced without
trailing growth [22].
In this study, we have specifically compared the therapeu-
tic activity of TTO and terpinen-4-ol in a well-established
experimental model of rat vaginal candidiasis, in which
the effect of immunotherapy by passive transfer of anti-
bodies, or active vaccination with whole Candida cells or
subunit antigens, has been assessed extensively [23-25].
This model has also been shown to be a valuable tool in
determining and predicting the antifungal activity of vari-
ous drugs, including the HIV-protease inhibitors [26].
This investigation was in part instigated by the numerous
claims and anecdotal reports on the therapeutic activity of
TTO against vaginal infections, including vaginal candi-
diasis. A potential advantage of novel therapeutics is their
capacity to inhibit micro-organisms that are resistant to
existing drugs; we therefore tested the in vivo activity of
TTO and terpinen-4-ol against a strain of C. albicans resist-
ant to FLC, one of the most popular and medically effec-
tive anti-Candida drugs. The results of our investigations
demonstrate that terpinen-4-ol treatment is efficacious in
substantially accelerating the experimental vaginal infec-
tion by C. albicans with both FLC-susceptible and -resist-
ant isolates. In the case of the drug-susceptible organism,
treatment with terpinen-4-ol was comparable to a stand-
ard treatment with FLC. In all cases, the infection was
resolved (using 1% v/v terpinen-4-ol) by the third week of
treatment. Importantly, terpinen-4-ol treatment was
equally efficacious against a azole-susceptible as well as
against a FLC-ITC resistant organism. Throughout this
investigation, there was no evidence of suffering by the
animals under terpinen-4-ol treatment, or any sign of
allergic response to a treatment that was easily dispensed
and non-chronic in nature (one intravaginal application a
day, for only the first 3 days, after intravaginal challenge).
Conclusion
Overall, our experimental data strengthen the previous
contribution [10] on TTO activity in vivo. In particular, we
have now identified for the first time terpinen-4-ol as a
single active in vivo constituent of TTO mixture. This high-
lights the therapeutic anti-Candida potential of a purified,
single component, thus avoiding the necessity of a labori-
ous and costly quality control of a mixture of compounds.
A clear need remains for pre-clinical and clinical investiga-
tions aimed at a more extensive assessment of terpinen-4-
ol, including studies on the mechanisms of anticandidal
activity.
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